| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institute of Cardiovascular Sciences (P.Z., B.L., B.S., G.H.), St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada R2H 2A6; and Department of Physiology (P.Z.), University of Manitoba, Winnipeg, Manitoba, Canada R3E 3J7
Address all correspondence and requests for reprints to: Peter Zahradka, Institute of Cardiovascular Sciences, Molecular Physiology Laboratory, St. Boniface Research Centre, 351 Tache Avenue, Winnipeg, Maniotoba, Canada R2H 2A6. E-mail: peterz{at}sbrc.ca.
Angiotensin II (AngII) activates phosphatidylinositol 3-kinase (PI3-kinase), a known effector of receptor tyrosine kinases. Treatment of smooth muscle cells with AngII has also been shown to promote phosphorylation of various tyrosine kinase receptors. We therefore investigated the relationship between AngII and IGF-I receptor activation in smooth muscle cells with a phosphorylation-specific antibody. Our experiments showed that IGF-I receptor phosphorylation was maximally stimulated within 10 min by AngII. Inclusion of an IGF-I-neutralizing antibody in the culture media did not prevent IGF-I receptor phosphorylation after AngII treatment, which argues that a paracrine/autocrine loop is not required. Furthermore, this process was blocked by losartan and 1-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP-1), indicating stimulation of IGF-I receptor phosphorylation occurs via AngII type 1 receptor-dependent activation of Src kinase. The functional significance of IGF-I receptor transactivation was examined with selective inhibitors of the IGF-I receptor kinase (AG1024, AG538). When AngII-treated cells were incubated with AG1024 or AG538, phosphorylation of the regulatory p85 subunit of PI3-kinase was blocked. Furthermore, phosphorylation of the downstream factor p70S6K did not occur. In contrast, AG1024 did not prevent MAPK or Src kinase activation by AngII. AG1024 also did not inhibit AngII-dependent cell migration, although this process was blocked by inhibitors of the epidermal growth factor and platelet-derived growth factor receptors. Transactivation of the IGF-I receptor is therefore a critical mediator of PI3-kinase activation by AngII but is not required for stimulation of the MAPK cascade.
This article has been cited by other articles:
 |
|
 |
|
  S. Bunda, P. Liu, Y. Wang, K. Liu, and A. Hinek Aldosterone Induces Elastin Production in Cardiac Fibroblasts through Activation of Insulin-Like Growth Factor-I Receptors in a Mineralocorticoid Receptor-Independent Manner Am. J. Pathol., September 1, 2007; 171(3): 809 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Lauzier, E. L. Page, M. D. Michaud, and D. E. Richard Differential Regulation of Hypoxia-Inducible Factor-1 through Receptor Tyrosine Kinase Transactivation in Vascular Smooth Muscle Cells Endocrinology, August 1, 2007; 148(8): 4023 - 4031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Martin and R. C. Baxter Expression of Insulin-Like Growth Factor Binding Protein-2 by MCF-7 Breast Cancer Cells Is Regulated through the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway Endocrinology, May 1, 2007; 148(5): 2532 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Junaid, M. C. Moon, G. E. J. Harding, and P. Zahradka Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1 Am J Physiol Cell Physiol, February 1, 2007; 292(2): C919 - C926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mojsilovic-Petrovic, G.-B. Jeong, A. Crocker, A. Arneja, S. David, D. Russell, and R. G. Kalb Protecting Motor Neurons from Toxic Insult by Antagonism of Adenosine A2a and Trk Receptors J. Neurosci., September 6, 2006; 26(36): 9250 - 9263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lieskovska, Y. Ling, J. Badley-Clarke, and D. R. Clemmons The Role of Src Kinase in Insulin-like Growth Factor-dependent Mitogenic Signaling in Vascular Smooth Muscle Cells J. Biol. Chem., September 1, 2006; 281(35): 25041 - 25053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Matthews, M. J. Taggart, and M. Westwood Effect of Cholesterol Depletion on Mitogenesis and Survival: The Role of Caveolar and Noncaveolar Domains in Insulin-Like Growth Factor-Mediated Cellular Function Endocrinology, December 1, 2005; 146(12): 5463 - 5473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Brywe, A.-L. Leverin, M. Gustavsson, C. Mallard, R. Granata, S. Destefanis, M. Volante, H. Hagberg, E. Ghigo, and J. Isgaard Growth Hormone-Releasing Peptide Hexarelin Reduces Neonatal Brain Injury and Alters Akt/Glycogen Synthase Kinase-3{beta} Phosphorylation Endocrinology, November 1, 2005; 146(11): 4665 - 4672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Juan, Y. Chien, L.-Y. Wu, W.-M. Yang, C.-L. Chang, Y.-H. Lai, P.-H. Ho, C. F. Kwok, and L.-T. Ho Angiotensin II Enhances Insulin Sensitivity in Vitro and in Vivo Endocrinology, May 1, 2005; 146(5): 2246 - 2254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bustamante, U. Hasler, O. Kotova, A. V. Chibalin, D. Mordasini, M. Rousselot, A. Vandewalle, P.-Y. Martin, and E. Feraille Insulin potentiates AVP-induced AQP2 expression in cultured renal collecting duct principal cells Am J Physiol Renal Physiol, February 1, 2005; 288(2): F334 - F344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hafizi, X. Wang, A. H. Chester, M. H. Yacoub, and C. G. Proud ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1232 - H1238. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
